Active, not recruitingPHASE1, PHASE2NCT04922723

Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
West Virginia University
Principal Investigator
Sonikpreet Aulakh, MD
WVU Cancer Institute
Intervention
Daratumumab(drug)
Enrollment
16 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04922723 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials